Antimicrobial lock solutions are important for prevention of microbial colonization and 25 infection of long-term central venous catheters. We investigated the efficacy and safety 26
In conclusion, PAD represents a novel antibiotic-free, non-cytotoxic lock solution that 38 elicits rapid and broad-spectrum eradication of biofilm-laden microbes and which shows 39 promise for the prevention and treatment of intravascular catheter infections. Central venous catheters (CVCs) provide long-term access to medication and total 48 parenteral nutrition for cancer, hemodialysis, short-gut, and transplant patients. The 49 majority of bloodstream infections in long-term CVCs (>10 days) is associated with 50 intraluminal microbial colonization (1,2). Current management guidelines for catheter-51 related bloodstream infections (CRBSIs) recommend use of antimicrobial lock therapy 52 (ALT) for catheter salvage (3). Even with antibiotics at concentrations 1,000-fold above 53 the systemic therapeutic dose, current ALT may be ineffective in eradicating mature 54 bacterial and fungal biofilms (4-7). In addition, leakage of antimicrobial lock solutions 55 into the bloodstream has been implicated in systemic toxicity in patients with long-term 56 CVCs, potential for increased biofilm formation, as well as adverse effects on the 57 catheter integrity and intraluminal precipitation (5-6,8-9). 58
After three decades of optimizing their utility in catheter lock solutions, reliance on 59 current antibiotics is fundamentally challenged by the limited scope to improve the 60 trade-off between efficacy and toxicity (6,7,10) and by the potential risk of antimicrobial 61 resistance (11). Inspired by the way that endogenous reactive oxygen species (ROS) 62 are released by immune cells of a mammalian host to inactivate invading bacteria, 63 extensive studies have shown that exogenous reactive oxygen and nitrogen species 64 (RONS) and other antimicrobial effectors (e.g. transient charges) generated by gas 65 plasmas effect rapid inactivation of bacteria and fungi (12) (13) (14) . In addition, RONS from 66 gas plasmas can be designed to be selective against microbes with little harm to 67 mammalian host (15, 16) . 68 4 We recently developed a novel gas plasma-activated disinfectant (PAD) as a 69 novel catheter lock solution. The aim of the current study was to determine the efficacy 70 of PAD against bacteria and fungi in a catheter biofilm model and to assess the effect of 71 PAD on primary human umbilical vein endothelial cells (HUVEC) as an in vitro model of 72 blood vessel endothelium. In doing so, we compared the PAD to a novel antibiotic-73 antiseptic lock solution. 74
75

MATERIALS AND METHODS 76
Catheter lock solutions 77
Minocycline hydrochloride (3 mg/ml) and EDTA (30 mg/ml) were mixed in 25% ethanol 78 (M-EDTA-25E), as a comparator lock solution (17). PAD was formed by treating 5 ml of 79 normal saline (NaCl) for 2 minutes with a room-temperature gas plasma system at 3.2 80 W in ambient air (18, Figure 1 ). Untreated saline was used as a control. A single colony was inoculated into 10 ml of appropriate broth, incubated overnight at 90 37°C while shaking at 160 rpm, harvested at mid-logarithmic phase growth by 91 5 centrifugation (500 x g, 5 min), then washed twice with 1xPBS. The inoculum 92 concentration was adjusted to 1.0 -2.0 x10 7 CFU/ml by broth dilution. 93
We modified a luminal biofilm model (4,19) using sterile silicone tubing of 1.58 94 mm ID, 3.175 mm OD (NewAge, Southampton, PA). Silicone tubing segments, 305 mm 95 in length, were sterilized and inoculated with approximately 600 µl of a prepared 96 microbial culture using a sterile syringe. Each inoculated catheter was sealed with a 97 sterile, tight-fitting PTFE plug, placed in a sterile Petri dish, and incubated without 98 shaking for 24 or 48 hours at 37°C. Inoculated segments were gently flushed with 99 normal saline, removing non-adherent microorganisms and leaving intact biofilm. 100 101
Eradication and regrowth assays 102
In the eradication assay, 600 µl of a test lock solution was slowly injected into the lumen 103 of each inoculated segment using a syringe. Segments were then incubated at 37°C for 104 15 -360 minutes. After incubation, the external surface of each segment was 105 thoroughly swabbed with 70% (v/v) ethanol and allowed to air dry to ensure that only 106 luminal microbes were recovered. Luminal contents were removed with a gentle saline 107 flush, each segment was then cut into three segments of 101.6 mm and submerged in 2 108 ml of 0.1 M glycine buffer (pH 7.0). Each of these segments was then vortexed for 1 109 minute, sonicated at 40 kHz for 1 minute in a room temperature water bath, then 110 vortexed for an additional minute. Luminal contents were then serially diluted and 111 colony counts were enumerated using a plate counter (detection limit 10 CFU/ml). 112
To evaluate microbial regrowth, catheter segments from each eradication 113 treatment were placed in a sterile 15 mil Falcon tube filled with 2 ml of appropriate broth 114 6 and incubated overnight with shaking at 37°C. Following incubation, segments were 115 vortexed for 1 minute, then sonicated for 1 minute. A 200 µl aliquot of sonicated broth 116 was used for serial dilution and plating. Plates were incubated overnight at 37°C before 117 colony enumeration. (Table 1A) . Complete suppression of regrowth 202 in the segment lumens was confirmed at 24 hours after an extended lock of 45 minutes 203 for bacteria and 60 minutes for C. albicans (Table 1B) . However, the M-EDTA-25E 204 treatment left a residual bacterial population of 3.0 -3.5 log 10 CFU/ml with 30-minute 205 incubation and a residual fungal population of 3.5 log 10 CFU/ml with 60-minute 206 10 incubation (Table 1A) . Furthermore, 24-hour incubation of segment lumens treated with 207 M-EDTA-25E lock solution for 60 minutes led to recovery of P. aeruginosa and C. 208 albicans, both to approximately 4.4 log 10 CFU/ml (Table 1B) . Against clinical isolates, 209 PAD lock for 60 minutes led to a 6-8 log reduction of all bacterial and fungal test 210 microorganisms (Table 2A ) and complete suppression of regrowth (Table 2B ). The 211 same 60-minute exposure to M-EDTA-25E lock solution resulted in approximately 2.8 212 log 10 CFU/ml of MRSA and S. epidermidis and 4.3 log 10 CFU/ml of C. albicans in 213 segment lumens (Table 2A ). Microbial recovery with M-EDTA-25E reached the initial 214 luminal inoculum of 7 -9 log 10 CFU/ml (Table 2B) . 215
A detailed comparison between PAD and M-EDTA-25E was made for eradication 216
and regrowth of C. albicans 14053 with extended lock times up to 360 minutes. 217
Complete regrowth inhibition of C. albicans biofilm required 360 min with M-EDTA-25E, 218 while a lock time of 60 minutes was needed for PAD (Table 3) . Efficacy with 60-minute 219 PAD lock solution was confirmed against 48-hour biofilms tested against microbes listed 220
in Table 1 ( 
data not shown). 221
To confirm effective biofilm dispersal, Figure 2A shows that 60-minute exposure 222 to PAD removed adhesive materials from inoculated glass slides with MRSA BAA-1707 223 and C. albicans 14053. By contrast, M-EDTA-25E exposure for 60 minutes led to 224 considerable biomass remaining on glass slides (Figure 2A ). Since adherent matter of P. 225
aeruginosa biofilms was most difficult to remove ( Figure 2B 
PAD effects on silicon catheter surface morphology 245
To test if the RONS in acidified PAD (Figure 1) impacts on catheter material after 246 repeated PAD locking, we performed an accelerated aging test by continuously locking 247 segments of catheter tubing for 7 days with regularly replenished PAD. In practice, 248 PAD locking for 2 hours per day is sufficient to ensure complete suppression of 249 microbial regrowth (Tables 1 and 2 ). There was no evidence of any episodes of fissures, 250 cracks, or other morphological abnormalities in PAD-treated catheter tubes (Figure 4) . Our study demonstrates that PAD lock solution is effective against microbial biofilms 255 implicated in CRBSI with minimal cytotoxicity to primary human vein epithelial cells. hours to achieve similar eradication and regrowth suppression. This is broadly in line 261
with the capability of current ALT that generally requires prolonged lock times (29, 30) . 262
Variable efficacy has been reported for current ALT and antifungal lock therapy 263 (AfLT) (29,30). For PAD therapy, effective lock times were approximately 60 minutes 264 against the Gram-positive and Gram-negative bacteria, and C. albicans we studied 265 (Table 1 , 2 and Figure 2 ). This suggests that PAD therapy can be applied prior to 266 identification of pathogens that may be involved in a suspected CRBSI episode. The 267 broad-spectrum antimicrobial properties of PAD are based on chemical diversity of 268 reactive oxygen, nitrogen and chlorine species (31), and collectively capable of 269 attacking different cellular targets (13,14) with minimal risk of systemic toxicity (Figure 3 ) 270 or damage to silicone catheters (Figure 4) . 271
An additional advantage of PAD is that we found minimal toxicity upon exposure 272 to primary human umbilical vein endothelial cells. This is likely benefited from pulsed 273 RONS of PAD (Figure 1 ) with which oxidative stresses to HUVECs are transient and as 274 13 such are more easily repaired than chemicals that generate reactive oxygen species in 275 living tissues for many months (32). Furthermore, continuous PAD locking for 7 days did 276 not result in any morphological abnormalities of silicone such as fissures, cracks or 277 damage when imaged using SEM (Figure 4) . The maximum daily exposure of a CVC to 278 PAD is 2 hours, and as such, the impact of continuous PAD locking for 7 days would be 279 equivalent to that of a 2-hour daily PAD therapy on an indwelling CVC for 84 hospital 280 days (=7x24/2). 281
Potential limitations to this study reflect the limited number of microbes included, 282 studies were not carried out in plasma or serum, only silicone material was tested and 283 additional testing was not performed to assess the impact of our PAD lock solution on 284 the silicone tubes (e.g., testing the modulus of elasticity, force at break, and maximum 285 stress at break). 286 PAD lock solution is free of antibiotics and the mechanism of action does not 287 involve specific binding sites on bacteria or fungi, thereby minimizing the risk of 288 selecting for antimicrobial resistance (11). In this context, it is of interest to note that a 2 289 hour exposure to a non-antibiotic containing, nitroglycerin-based lock solution reduces 290 bacteria and fungal intraluminal biofilms by 4 orders of magnitude (19,34). Nitroglycerin 291 produces reactive oxygen and nitrogen species (35) and this may explain why its 292 activity against bacteria and fungi is similarly broad spectrum to PAD. Taken together, 293 PAD lock therapy may be an innovative addition to current ALT and AfLT. <1 <1 a P ≤ 0.001 when compared with control; n = 3; detection limit 1 log 10 CFU/ml. c P ≤ 0.05 when compared with control; n = 3; detection limit 1 log 10 CFU/ml. a P ≤ 0.001 when compared with control; n = 3; detection limit 1 log 10 CFU/ml.
